Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 83

Sort by

Sort Order Select

Journal Articles

RAS Pathway Mutations Are Associated with Progression after Hypomethylating Agent Therapy in Chronic Myelomonocytic Leukemia

Guillermo Montalban-Bravo, Faezeh Darbaniyan, Kelly S. Chien, Danielle Hammond, Rashmi Kanagal-Shamanna, Tapan M. Kadia, Courtney D. DiNardo, Naval Daver, Farhad Ravandi, Elias Jabbour, Naveen Pemmaraju, Nicholas Short, Koichi Takahashi, Zeev E. Estrov, Sherry A. Pierce, Hagop Kantarjian, Guillermo Garcia-Manero

Blood (2022) 140 (Supplement 1): 4036–4038.

https://doi.org/10.1182/blood-2022-170069

Published: 2022

Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data

Blood (2022) 140 (Supplement 1): 234–237.

https://doi.org/10.1182/blood-2022-170850

Published: 2022

Journal Articles

Early Treatment with Ofatumumab in Patients with High-Risk CLL

Sai Prasad Desikan, Michael J. Keating, Alessandra Ferrajoli, Nitin Jain, Maro Ohanian, Naveen Pemmaraju, Courtney D. DiNardo, Marina Konopleva, Tapan M. Kadia, Susan O'Brien, Zeev E. Estrov, Deborah A Thomas, Jan A. Burger, Philip A. Thompson, William G. Wierda

Blood (2022) 140 (Supplement 1): 9876–9878.

https://doi.org/10.1182/blood-2022-167284

Published: 2022

Journal Articles

Long Term Results of Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocythemia and Polycythemia Vera: Median Follow-up of 15 Years

Lucia Masarova, Prithviraj Bose, Naveen Pemmaraju, Mary Ann Richie, Gautam Borthakur, Zeev E. Estrov, Hagop Kantarjian, Keyur P. Patel, Srdan Verstovsek

Blood (2022) 140 (Supplement 1): 9683–9684.

https://doi.org/10.1182/blood-2022-165538

Published: 2022

Journal Articles

Phase II Trial of Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Outcomes in Genomic Subgroups

Blood (2021) 138 (Supplement 1): 694.

https://doi.org/10.1182/blood-2021-153227

Published: 2021

Journal Articles

Outcomes of Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents

Sangeetha Venugopal, Kelly S. Chien, Danielle Hammond, Rashmi Kanagal-Shamanna, Koji Sasaki, Tapan M. Kadia, Courtney D. DiNardo, Marina Konopleva, Naval Daver, Farhad Ravandi, Naveen Pemmaraju, Nicholas J. Short, Ghayas C. Issa, Koichi Takahashi, Zeev E. Estrov, Sherry A. Pierce, Hagop Kantarjian, Guillermo Garcia-Manero, Guillermo Montalban-Bravo

Blood (2021) 138 (Supplement 1): 2613.

https://doi.org/10.1182/blood-2021-153475

Published: 2021

Journal Articles

Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Updated Results of a Phase II Trial

Blood (2021) 138 (Supplement 1): 1270.

https://doi.org/10.1182/blood-2021-153530

Published: 2021

Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD Results

Blood (2021) 138 (Supplement 1): 3720.

https://doi.org/10.1182/blood-2021-154454

Published: 2021

Journal Articles

Expansion of T Follicular Helper Cells in NLC Co-Cultures Reinforces the Concept of Co-Evolution of CLL and Supportive T Helper Cell Clones

Alicia Vaca, Nikolaos Ioannou, Mariela Sivina, Elisavet Vlachonikola, Karen Clise-Dwyer, Ekaterina Kim, Dan Li, Qing Ma, Alessandra Ferrajoli, Zeev E. Estrov, William G. Wierda, Piers E.M. Patten, Alan G. Ramsay, Jan A. Burger

Blood (2021) 138 (Supplement 1): 3716.

https://doi.org/10.1182/blood-2021-151351

Published: 2021

Journal Articles

A Pilot Study of the Anti-SLAMF7 Monoclonal Antibody, Elotuzumab, in Myelofibrosis

Prithviraj Bose, Taghi Manshouri, Sharon D. Bledsoe, Nitin Jain, Lucia Masarova, Naveen Pemmaraju, Nakiuda Hall, Mary Ann Richie, Xuemei Wang, Hagop Kantarjian, Zeev E. Estrov, Srdan Verstovsek

Blood (2021) 138 (Supplement 1): 3635.

https://doi.org/10.1182/blood-2021-145750

Published: 2021

Journal Articles

Clinical Features Associated with Long-Term Ruxolitinib Exposure in Myelofibrosis and Predictive Role of Neutrophils

Lucia Masarova, Prithviraj Bose, Naveen Pemmaraju, Lingsha Zhou, Sherry A. Pierce, Zeev E. Estrov, Hagop Kantarjian, Srdan Verstovsek

Blood (2021) 138 (Supplement 1): 3633.

https://doi.org/10.1182/blood-2021-154267

Published: 2021

Journal Articles

Updated Results of a Phase 1/2 Study of Lower Dose CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia after Failure to Hypomethylating Agents

Guillermo Montalban-Bravo, Elias J. Jabbour, Zeev E. Estrov, Tapan M. Kadia, Farhad Ravandi, Kelly S. Chien, Graciela M. Nogueras González, Xiao Qin Dong, Stefan Faderl, Heather Schneider, Rosmy B. John, Meghan Anne Meyer, Hagop Kantarjian, Guillermo Garcia-Manero

Blood (2021) 138 (Supplement 1): 3674.

https://doi.org/10.1182/blood-2021-151493

Published: 2021

Journal Articles

Long-Term Outcome of Treatment-Naïve and Relapsed/Refractory Patients with CLL and TP53 Aberrations Treated with Ibrutinib, with or without Rituximab

Mariela Sivina, Ekaterina Kim, William G. Wierda, Alessandra Ferrajoli, Nitin Jain, Philip A. Thompson, Zeev E. Estrov, Hagop Kantarjian, Michael J. Keating, Jan A. Burger

Blood (2021) 138 (Supplement 1): 3734.

https://doi.org/10.1182/blood-2021-151711

Published: 2021

Journal Articles

Assessment of Immunoglobulin Heavy Chain Variable Region ( IGHV ) Mutation Status with a Next-Generation Sequencing (NGS) Immunosequencing Assay for Measurable Residual Disease (MRD)

Lik Wee Lee, Travers Ching, Bryan Howie, Keyur P. Patel, Philip A. Thompson, Nitin Jain, Alessandra Ferrajoli, Zeev E. Estrov, Jan A. Burger, Michael J. Keating, Rashmi Kanagal-Shamanna, William G. Wierda, Lanny R. Kirsch

Blood (2021) 138 (Supplement 1): 4676.

https://doi.org/10.1182/blood-2021-146611

Published: 2021

Journal Articles

Final Results of a Phase 2 Study of Sotatercept (ACE-011) for Anemia of MPN-Associated Myelofibrosis

Blood (2021) 138 (Supplement 1): 144.

https://doi.org/10.1182/blood-2021-150908

Published: 2021

Journal Articles

Retrospective Single-Institution Analysis of Patients with Chronic Lymphocytic Leukemia with TP53 alterations Treated First-Line with Bruton's Tyrosine Kinase Inhibitor-Based Therapy

Hua-Jay J. Cherng, Raamis Khwaja, Rashmi Kanagal-Shamanna, Jan A. Burger, Philip A. Thompson, Alessandra Ferrajoli, Zeev E. Estrov, Koji Sasaki, Deepa Sampath, Guilin Tang, Xuemei Wang, Hagop Kantarjian, Michael J. Keating, William G. Wierda, Nitin Jain

Blood (2021) 138 (Supplement 1): 394.

https://doi.org/10.1182/blood-2021-146432

Published: 2021

Journal Articles

Characteristics and Outcome of Myelofibrosis Patients on Long-Term Ruxolitinib Therapy (≥3 years)

Lucia Masarova, MD, Prithviraj Bose, MD, Naveen Pemmaraju, MD, Lingsha Zhou, Sherry A. Pierce, BSN, BA, Hagop M. Kantarjian, MD, Zeev E. Estrov, MD, Srdan Verstovsek, MD PhD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-142554

Published: 2020

Journal Articles

Initial Results of a Phase 1 Dose Escalation Study of CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) after Failure to Hypomethylating Agents

Guillermo Montalban Bravo, MD, Elias Jabbour, MD, Tapan M. Kadia, MD, Farhad Ravandi, MBBS, Zeev E. Estrov, MD, Kiran Naqvi, MD MPH, Koji Sasaki, MD, Kelly S. Chien, MD, Graciela M. Nogueras González, MPH, Xiao Qin Dong, Stefan Faderl, MD, Heather Schneider, BSN, RN, Rosmy B. John, MSN, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-139942

Published: 2020

Journal Articles

Response and Survival Outcomes with Hypomethylating Agents in Patients with Chronic Myelomonocytic Leukemia Based on Disease Phenotype and Risk Categories

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-142469

Published: 2020

Journal Articles

Predictors of Early Mortality, Response, and Survival in Newly Diagnosed Acute Myeloid Leukemia (AML) Using a Contemporary Academic Cohort

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-141837

Published: 2020

NARROW

RAS Pathway Mutations Are Associated with Progression after Hypomethylating Agent Therapy in Chronic Myelomonocytic Leukemia

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data

Early Treatment with Ofatumumab in Patients with High-Risk CLL

Long Term Results of Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocythemia and Polycythemia Vera: Median Follow-up of 15 Years

Phase II Trial of Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Outcomes in Genomic Subgroups

Outcomes of Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents

Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Updated Results of a Phase II Trial

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD Results

Expansion of T Follicular Helper Cells in NLC Co-Cultures Reinforces the Concept of Co-Evolution of CLL and Supportive T Helper Cell Clones

A Pilot Study of the Anti-SLAMF7 Monoclonal Antibody, Elotuzumab, in Myelofibrosis

Clinical Features Associated with Long-Term Ruxolitinib Exposure in Myelofibrosis and Predictive Role of Neutrophils

Updated Results of a Phase 1/2 Study of Lower Dose CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia after Failure to Hypomethylating Agents

Long-Term Outcome of Treatment-Naïve and Relapsed/Refractory Patients with CLL and TP53 Aberrations Treated with Ibrutinib, with or without Rituximab

Assessment of Immunoglobulin Heavy Chain Variable Region ( IGHV ) Mutation Status with a Next-Generation Sequencing (NGS) Immunosequencing Assay for Measurable Residual Disease (MRD)

Final Results of a Phase 2 Study of Sotatercept (ACE-011) for Anemia of MPN-Associated Myelofibrosis

Retrospective Single-Institution Analysis of Patients with Chronic Lymphocytic Leukemia with TP53 alterations Treated First-Line with Bruton's Tyrosine Kinase Inhibitor-Based Therapy

Characteristics and Outcome of Myelofibrosis Patients on Long-Term Ruxolitinib Therapy (≥3 years)

Initial Results of a Phase 1 Dose Escalation Study of CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) after Failure to Hypomethylating Agents

Response and Survival Outcomes with Hypomethylating Agents in Patients with Chronic Myelomonocytic Leukemia Based on Disease Phenotype and Risk Categories

Predictors of Early Mortality, Response, and Survival in Newly Diagnosed Acute Myeloid Leukemia (AML) Using a Contemporary Academic Cohort

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only